PHVS jumps after positive topline HAE trial results
Pharvaris (PHVS) shares rose after the company disclosed positive topline data from a hereditary angioedema (HAE) trial. The stock gained 11% to $39.26 on Tuesday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.